全聘课题组长
首页  人才队伍  全聘课题组长
  • 许杰

    博士,研究员,博士生导师
     地址:东安路131号,明道楼903室,上海 200032
     电话:021-54237807
     传真:021-54237283
     邮箱:jie_xu@fudan.edu.cn


工作经历
研究员 复旦大学,生物医学研究院 (2019.08-今)
研究员 上海交通大学医学院 (2015.12-2019.07)
副研究员 上海交通大学医学院 (2012.01-2015.11)
博士后 比利时弗兰德斯生物技术研究所(2010.07-2011.12)
医师 同济大学附属第十人民医院普外科(2005.08-2006.08)
教育经历
博士 布鲁塞尔自由大学,生命科学工程 (2006.09-2010.06)
学士、硕士 哈尔滨医科大学, 临床医学(七年制) (1998.09-2005.07)
所获人才项目
国家“万人计划”青年拔尖人才, 2015
国家自然科学基金优青,2013
仲英青年学者,2016
上海市曙光学者,2015
上海高校特聘教授,2013
上海市浦江人才,2013
欧盟优秀博士后奖励计划,2010
上海市青年科技启明星,2006
所获奖项

上海市卫生系统银蛇奖二等奖 2015
国家科学技术进步奖二等奖(第四完成人) 2018
上海市科学技术进步奖一等奖(第三完成人)2014
教育部高等学校科学研究优秀成果奖(第五完成人)2013


研究方向

专注于恶性肿瘤的转化医学研究,在揭示免疫检查点和癌变相关蛋白调控机制的基础上,探索蛋白质靶向降解(POTAC, LYTAC等)的新方法,为肿瘤的靶向与免疫治疗提供药物先导化合物:发现HIP1R调控PD-L1溶酶体降解的分子机制,并根据其“结合-分选”的作用模式设计了PD-LYSO靶向降解肽(Nat Chem Biol 2019);发现DHHC3对PD-L1进行棕榈酰化修饰,并以“诱饵底物”设计靶向分子PD-PALM(Nat Biomed Eng 2019);发现DHHC9对PD-1的棕榈酰化修饰,并设计PD1-PALM抑制剂(RSC Chem. Biol. 2020);根据Morn3的功能设计新型p53靶向分子用于抑制直肠癌的增殖(Cell Chem Biol 2018),针对MAPK、NFKB、WNT、RhoGAP、p53等通路调控机制的研究,以通讯作者发表论文于JNCI,GUT, Cancer Res, Oncogene, Nature Commun, Cell Rep等期刊;作为主编撰写Springer Nature出版的《Regulation of Cancer Immune Checkpoints》一书;担任Frontiers in Pharmacology和BMC Cancer副主编;作为主要发明人开发了结直肠癌早期无创筛查试剂盒并完成了专利的转让;作为负责人承担国家自然科学基金重点项目、优青、面上等项目,以及国家重点研发计划课题;获得上海市卫生系统“银蛇奖”二等奖。


代表论文

1.Jie Xu (*), Jean-Philippe Brosseau, and Hubing Shi, Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene. 2020; DOI: 10.1038/s41388-020-01491-w

2.Yao H, Li C, He F, Song T, Brosseau JP, Wang H, Lu H, Fang C, Shi H, Lan J, Fang JY, and Xu J(*). Peptidic inhibitor for PD-1 palmitoylation targets cancer intrinsic expression and functions. RSC Chemical Biology. 2020.

3.Wang YT, Shi H, Meng H, Xu J(*).Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies. Front. Pharmacol. doi: 10.3389/fphar.2020.591188

4.Yungang Wang, Shouyan Deng, Jie Xu(*), Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets. Cancer Biolology & Medicine. 2020;17(3):583-598

5.Xu, J (*). (2020). Regulation of Cancer Immune Checkpoints.Springer Nature. Hardcover ISBN: 9811532656. Pages 1-653. (*Book Editor)

6.Wang, Huanbin(#); Yao, Han; Li, Chushu; Shi, Hubing; Lan, Jiang; Li, Zhaoli; Zhang, Yao; Liang, Lunxi; Fang, Jing-Yuan; Xu, Jie(*), HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nature Chemical Biology, 2019 (1): 42~50

7.Han Yao; Jiang Lan; Chushu Li; Hubing Shi; Jean-Philippe Brosseau; Huanbin Wang; Haojie Lu; Caiyun Fang; Yao Zhang; Lunxi Liang; Xiaolin Zhou; Chaojun Wang; Yu Xue; Yun Cui; Jie Xu (*), Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours, Nature Biomedical Engineering, 2019; 3(5):414

8.Liang L(#), Wang H(#), Shi H, Li Z, Yao H, Bu Z, Song N, Li C, Xiang D, Zhang Y, Wang J, Hu Y, Xu Q, Ma Y, Cheng Z, Wang Y, Zhao S, Qian J, Chen Y, Fang JY, Xu, J (*), A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity, Cell Chemical Biology, 2018, 25(6): 761~774

9.YitingWang, HuanbinWang, HanYao, ChushuLi, Jing-YuanFang, Xu, J (*). Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Front Pharmacol. 2018; 9:536.

10.Qian J, Li Y, Yao H, Tian H, Wang H, Ai L, Xie Y, Bao Y, Liang L, Hu Y, Zhang Y, Wang J, Li C, Tang J, Chen Y, Xu, J (*), Fang JY(*). ASAP3 regulates microvilli structure in parietal cells and presents intervention target for gastric acidity. Signal Transduction & Targeted Therapy. 2017; 2:17003

11.Wang, Huanbin(#); Yao, Han(#); Li, Chushu; Liang, Lunxi; Zhang, Yao; Shi, Hubing; Zhou, Chongzhi; Chen, Yingxuan; Fang, Jing-Yuan; Xu, Jie (*), PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylationOncoimmunology, 2017, 6(7): e1327494

12.Zhang, Y.(#); Hu, Y.(#); Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Shi, H.; Chen, Y.; Fang, J-Y; Xu, J.(*), Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp, Oncogene, 2017, 36(39): 5473~5483

13.Yao, Han(#); Wang, Huanbin; Li, Chushu; Fang, Jing-Yuan; Xu, Jie; Xu, J (*), Cancer Cell-intrinsic PD-1 and implications in Combinatorial immunotherapy, Frontiers in Immunology, 2018, 9(1774): 0~1774

14.Wang H(#); Liang L; Fang JY; Xu J (*), Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers, Oncogene, 2015, 35(304): 2011~2019  

15.Xie, Yuan-Hong(#); Gao, Qin-Yan; Zou, Tian-Hui; Chen, Hui-Min; Yu, Si-Yi; Qiu, Yi-Wen; Gu, Wei-Qi; Chen, Xiao-Yu; Cui, Yun; Sun, Danfeng; Xu, Jie; Chen, Ying-Xuan; Fang, Jing-Yuan; Cai, Guo-Xiang; Cai, San-Jun; Sun, Xiao-Ming; Liu, Zhan-Ju; Cai, SJ(*)Xu, J (*); Chen, YX(*); Fang, JY(*), Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies, EBioMedicine, 2017, 25: 32~40

16.Qian, Jin(#); Kong, Xuan(#); Deng, Niantao; Tan, Patrick; Chen, Haoyan; Wang, Jilin; Li, Zhaoli; Hu, Ye; Zou, Weiping; Xu, Jie (*); Fang, Jing-Yuan(*), OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer, Gut, 2015, 64(1): 37~48  

17.Liang L(#); Fang JY(*)Xu J (*), Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy, Oncogene, 2015, 35(12): 1475~1482

18.Wang, Jilin(#); Qian, Jin(#); Hu, Ye; Kong, Xuan; Chen, Haoyan; Shi, Qinghua; Jiang, Long; Wu, Chenming; Zou, Weiping; Chen, Yingxuan; Xu, Jie (*); Fang, Jing-Yuan(*), ArhGAP30 promotes p53 acetylation and function in colorectal cancer, Nature Communications, 2014, 5: 5735

19.Hu, Ye(#); Wang, Jilin; Qian, Jin; Kong, Xuan; Tang, Jieting; Wang, Yingchao; Chen, Haoyan; Hong, Jie; Zou, Weiping; Chen, Yingxuan; Xu, Jie (*); Fang, Jing-Yuan(*), Long Noncoding RNA GAPLINC Regulates CD44-Dependent Cell Invasiveness and Associates with Poor Prognosis of Gastric Cancer, Cancer Research, 2014, 74(23): 6890~6902

20.Xuan Kong, Jin Qian, Li-Sha Chen, Ying-Chao Wang, Ji-Lin Wang, Haoyan Chen, Yu-Rong Weng, Shu-Liang Zhao, Jie Hong, Ying-Xuan Chen, Weiping Zou, Jie Xu (*), Jing-Yuan Fang(*), Synbindin in Extracellular Signal-Regulated Protein Kinase Spatial Regulation and Gastric Cancer Aggressiveness, JNCI:Journal of the National Cancer Institute, 2013, 105(22):1738-49



Top